Recent Updates
Recently added Catalysts
GH Positive Sentiment

Guardant Health to Appeal Federal District Court Judgment

Monday, August 24, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Guardant Health, Inc. has announced plans to appeal a final judgment from the U.S. District Court for the District of Delaware regarding intellectual property claims by TwinStrand Biosciences and the University of Washington. The execution of the judgment and any potential royalty collections are currently stayed pending the outcome of the appeal. Guardant Health expresses strong disagreement with the court's decision.

Market Sentiment Analysis

POSITIVE FACTORS

  • Guardant Health is taking action to appeal the judgment.
  • The execution of the judgment is stayed pending appeal.
  • The company maintains confidence in its position.

CONCERNS & RISKS

  • The company faces intellectual property claims.
  • Potential royalties may be involved if the appeal fails.

Full Press Release Details

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington, with execution of the final judgment and collection of potential royalties stayed pending appeal. “We strongly disagree with this decision and will prompt

Frequently Asked Questions

What is the reason for Guardant Health's appeal?

Guardant Health is appealing a judgment related to intellectual property claims.

Who brought the claims against Guardant Health?

The claims were brought by TwinStrand Biosciences and the University of Washington.

What is the status of the judgment during the appeal?

The execution of the judgment and collection of royalties are stayed pending appeal.

How does Guardant Health feel about the court's decision?

Guardant Health strongly disagrees with the court's decision.

ShareAdd on Google
Tags: GH Viatris Investor Conferences Healthcare Guardant Health TwinStrand Biosciences University of Washington intellectual property court judgment
Last updated: Aug 24, 2026

Biotech snapshot

Cash runway
$1053M liquidity · $19M/mo burn
~54 mo
Minimal dilution risk